Chemistry:Merestinib
From HandWiki
Short description: Experimental cancer drug
 | |
| Clinical data | |
|---|---|
| Routes of administration | PO |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C30H22F2N6O3 |
| Molar mass | 552.542 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Merestinib (LY2801653) is an experimental cancer drug in development by Eli Lilly. It is a small molecule inhibitor of MET and several other receptor tyrosine kinases such as MST1R, FLT3, AXL, MERTK, TEK, ROS1, NTRK1/2/3, and DDR1/2.[1]
Meristinib is part of a phase II clinical trial for advanced billiary tract cancer. The study is expected to be complete in April 2018.[2] Phase II clinical trials for non-small cell lung cancer and solid tumors began in November 2016.[3]
References
- ↑ "Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors". Oncotarget 9 (17): 13796–13806. March 2018. doi:10.18632/oncotarget.24488. PMID 29568395.
- ↑ Clinical trial number NCT02711553 for "A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer" at ClinicalTrials.gov
- ↑ "Merestinib - Eli Lilly". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800033685.
 |  |
